Crizanlizumab-TMCA Drug Asset Due Diligence Report 2026

This Crizanlizumab-TMCA Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Crizanlizumab-TMCA can convert its Monoclonal antibody profile and P-sel biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Crizanlizumab-TMCA (query alias: crizanlizumab)
Modality / target	Monoclonal antibody; P-sel; P-sel inhibitors
Highest global status	Approved
Originator	Novartis Pharma AG
Active developers	Novartis Pharmaceuticals Corp., Novartis Pharmaceuticals Canada, Inc., Novartis Pharma AG

The MCP disease footprint includes Anemia, Sickle Cell, Vaso-occlusive crisis, Sickle Cell Trait. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT06439082	Phase 3	Recruiting	315	Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment arm
NCT05909618	Phase 2	Recruiting	33	Incidence of treatment-related adverse, serious adverse events, immune-related AEs following treatment with crizanlizumab alone or in combination with nivolumab
NCT05469828	Phase 1/2	Not yet recruiting	30	The investigators will test whether SEG101 improves Supply-Demand Matching in patients with sickle cell anemia by measuring the change in tissue oxygenation by near infrared spectroscopy from baseline to 3 months and to 6 months.

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

A phase III, multicenter, randomized, placebo controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult sickle cell disease patients with frequent vaso-occlusive crises: The sparkle study

Phase 3; n=315; evaluation: Positive. Reported fields: TEAE(serious) = 20.0 % ; TEAE(serious) = 19.0 %

Effect of P2Y12 Inhibitors, SGLT2 Inhibitors and P-Selectin Inhibitors on One-year Quality-of-Life Outcomes in Critically Ill Patients Hospitalized for COVID-19: A Pre-specified Secondary Analysis of the ACTIV4a Randomized Clinical Trial

Not Applicable; n=750; evaluation: Negative. Reported fields: Mental health = -4.09 PROMIS t-score ; Mental health = -4.09 PROMIS t-score ; Mental health = -4.09 PROMIS t-score

INDIVIDUAL PATIENT ADHESIVE PHENOTYPES DEFINED BY FLOW ADHESION OF WHOLE BLOOD TO P-SELECTIN PREDICTS BIOLOGIC RESPONSE TO CRIZANLIZUMAB ADMINISTERED IN THE REAL WORLD CLINICAL SETTING

Not Applicable; n=994; evaluation: Positive. Reported fields: FA-WB-Psel = 50 cells/mm² ; FA-WB-Psel = 50 cells/mm² ; FA-WB-Psel = 50 cells/mm²

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Crizanlizumab-TMCA addresses Anemia, Sickle Cell, Vaso-occlusive crisis, Sickle Cell Trait. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: P-sel records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2022-08-08	Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology	Phase 2/3	US$5,400.0M stated total
2021-03-12	GBT Expands Sickle Cell Disease Pipeline with Exclusive In-license of Two Novel Small Molecule Programs from Sanofi S.A.	Phase 1	US$353.0M milestones
2020-02-28	GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Year-end 2019, with Pfizer Returning Rivipansel Rights	Phase 2	US$340.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “P-selectin inhibition for treatment of cancer”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO